FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Related Tags >> Phase III   NeurogesX   NGX-4010   layoffs
Syndicate content

Postherpetic Neuralgia News

Most Popular Postherpetic Neuralgia Story

NeurogesX reports positive Phase III data

NeurogesX is touting positive data from the second late-stage study of NGX-4010, a dermal patch therapy for patients with postherpetic neuralgia. The study hit its primary endpoint with a 32 percent... Read more...

Latest Headlines